Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
This article examines Why Do Stablecoins Fail, focusing on reserve adequacy, liquidity mismanagement, and governance gaps that threaten peg stability.
17,914 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A family-friendly theater warning highlights a common scam: fake ticket listings that imitate legitimate sites. Learn...
Red Cat Holdings posted a record Q4 revenue of $26.2 million and full-year $40.7 million, but margins stayed thin and...
As Medicare costs rise in 2026, a diversified income plan offers a path to cover health coverage indefinitely. Expert...
A federal lawsuit claims Meta’s Ray-Ban AI glasses expose user footage to human reviewers overseas, challenging the c...
May 2026 hands investors a surprise: a big jump in M2 money supply could rekindle inflation pressures. Markets weigh ...
A Crinetics director sells 5,000 shares as the stock dips. This guide breaks down what insider moves really mean for ...
A public figure’s passing highlights how royalties, catalogs, and estate planning shape financial security. This arti...
A 58-year-old nurse with 230K saved is advised to buy a condo and ramp retirement funding, with a potential 350K inhe...
On July 1, 2026, SOXL tumbled 16% in a single session as its leveraged structure amplified the move. The fallout reve...